Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas
Sponsor: M.D. Anderson Cancer Center
This PHASE2 trial investigates Diffuse Large Cell Lymphoma and Lymphoma and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .